HOLON, Israel, Nov. 11,
2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq:
CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company
and a pioneer in computational target discovery,
today announced that Compugen management will participate in a
fireside chat at the upcoming Stifel 2024 Healthcare Conference in
New York City. The fireside chat
will take place on Monday, November 18,
2024 at 8:35 am ET.
A live webcast will be accessible on the Investor Relations
section of the Compugen website at www.cgen.com. A replay will
also be available following the live event.
About Compugen
Compugen is a clinical-stage
therapeutic discovery and development company utilizing its broadly
applicable predictive computational discovery platform
(UnigenTM) to identify new drug targets and biological
pathways for developing cancer immunotherapies. Compugen has two
proprietary product candidates in Phase 1 development: COM701, a
potential first-in-class anti-PVRIG antibody and COM902, a
potential best-in-class antibody targeting TIGIT for the treatment
of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody
where the TIGIT component is derived from Compugen's clinical stage
anti-TIGIT antibody, COM902, is in Phase 3 development by
AstraZeneca through a license agreement for the development of
bispecific and multispecific antibodies. In addition, the
Company's therapeutic pipeline of early-stage immuno-oncology
programs consists of programs aiming to address various mechanisms
of immune resistance, of which the most advanced program, COM503, a
potential first-in-class, high affinity anti-IL-18 binding protein
antibody, which has been granted IND clearance from the FDA, is
licensed to Gilead. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Company contact:
Yvonne
Naughton, Ph.D.
VP, Head of Investor Relations, and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-stifel-2024-healthcare-conference-302301103.html
SOURCE Compugen Ltd.